ENVB
Enveric Biosciences, Inc.·Healthcare
1.96
3.713%(−0.08)
Market ClosedLast Updated: — ET
52W L: $1.7552W H: $17.84
ENVB NEWS
businesswire.com
Mar 31
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 (“the'232 patent”) from the United States Patent and Trademark Office (USPTO) pertaining to its EVM301 Series of molecules. The EVM301 Series includes lead candidate, EB-003, being dev.
businesswire.com
Mar 27
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today provided a corporate update following the filing of its 10-K on Friday, March 27, 2026, which reported financial results for the fourth quarter and year ended December 31, 2025. CEO Commentary: “The year 2025 was a year of important scientific progress for En.
businesswire.com
Mar 18
Enveric Biosciences Announces Registration of Five Trademarks
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company's trademarks, including its house marks, Enveric and Enveric Biosciences. “The registration of a Company's house marks, such as our marks Enveric and Enveric Bioscie.
businesswire.com
Feb 25
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric's issued U.S. Patent No. 12,138,276 (the '276 patent) has been withdrawn. This action follows Enveric's filing of a Reque.
businesswire.com
Feb 19
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activation.
businesswire.com
Jan 29
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. (“TOTEC”) its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology (“Aries”), is advancing the commercializati.
